Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Legend Biotech (LEGN) Other Non-Current Assets: 2020-2024

Historic Other Non-Current Assets for Legend Biotech (LEGN) over the last 5 years, with Dec 2024 value amounting to $6.1 million.

  • Legend Biotech's Other Non-Current Assets rose 468.84% to $11.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.0 million, marking a year-over-year increase of 468.84%. This contributed to the annual value of $6.1 million for FY2024, which is 305.63% up from last year.
  • Legend Biotech's Other Non-Current Assets amounted to $6.1 million in FY2024, which was up 305.63% from $1.5 million recorded in FY2023.
  • In the past 5 years, Legend Biotech's Other Non-Current Assets registered a high of $13.2 million during FY2020, and its lowest value of $1.5 million during FY2022.
  • Its 3-year average for Other Non-Current Assets is $3.0 million, with a median of $1.5 million in 2023.
  • Its Other Non-Current Assets has fluctuated over the past 5 years, first tumbled by 71.11% in 2022, then skyrocketed by 305.63% in 2024.
  • Legend Biotech's Other Non-Current Assets (Yearly) stood at $13.2 million in 2020, then plummeted by 60.97% to $5.1 million in 2021, then slumped by 71.11% to $1.5 million in 2022, then climbed by 0.40% to $1.5 million in 2023, then surged by 305.63% to $6.1 million in 2024.